The use of targeted therapy significantly improved ORR and PFS in patients with a long-term PFS benefit at one year and ...

In the Phase I trial, the duration of response to Regeneron's combination therapy continued beyond two years in melanoma ...

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Metastatic solid tumors may be curable now. Among the most profound results presented over the weekend at the European ...

Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. Radioligand ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...